SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 328 filers reported holding SAREPTA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.82 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $174,040,524 | -20.3% | 1,435,741 | -24.7% | 0.04% | -18.2% |
| Q2 2023 | $218,316,461 | +17.5% | 1,906,361 | +41.4% | 0.04% | +12.8% |
| Q1 2023 | $185,798,561 | +112.2% | 1,348,027 | +99.5% | 0.04% | +77.3% |
| Q4 2022 | $87,563,296 | +65.7% | 675,747 | +41.4% | 0.02% | +57.1% |
| Q3 2022 | $52,840,000 | +72.4% | 478,016 | +16.9% | 0.01% | +100.0% |
| Q2 2022 | $30,643,000 | -20.8% | 408,792 | -17.5% | 0.01% | +16.7% |
| Q1 2022 | $38,705,000 | -78.4% | 495,458 | -75.1% | 0.01% | 0.0% |
| Q4 2021 | $178,986,000 | +119.0% | 1,987,634 | +124.9% | 0.01% | -45.5% |
| Q3 2021 | $81,718,000 | +22.2% | 883,619 | +2.7% | 0.01% | +22.2% |
| Q2 2021 | $66,866,000 | -1.6% | 860,131 | -5.6% | 0.01% | -18.2% |
| Q1 2021 | $67,942,000 | -85.3% | 911,620 | -66.3% | 0.01% | -71.1% |
| Q4 2020 | $461,070,000 | +197.8% | 2,704,386 | +145.3% | 0.04% | +26.7% |
| Q3 2020 | $154,813,000 | -12.1% | 1,102,431 | +0.3% | 0.03% | -28.6% |
| Q2 2020 | $176,161,000 | +114.9% | 1,098,676 | +31.1% | 0.04% | +55.6% |
| Q1 2020 | $81,973,000 | -73.7% | 837,995 | -65.3% | 0.03% | -70.0% |
| Q4 2019 | $311,919,000 | +50.6% | 2,417,229 | -12.1% | 0.09% | +30.4% |
| Q3 2019 | $207,149,000 | -82.3% | 2,750,239 | -64.2% | 0.07% | -52.4% |
| Q2 2019 | $1,167,692,000 | +347.5% | 7,684,703 | +251.0% | 0.14% | +35.5% |
| Q1 2019 | $260,944,000 | +53.2% | 2,189,310 | +40.3% | 0.11% | +59.7% |
| Q4 2018 | $170,328,000 | -57.5% | 1,560,777 | -37.1% | 0.07% | -48.9% |
| Q3 2018 | $400,684,000 | -0.5% | 2,480,860 | -18.5% | 0.13% | -5.8% |
| Q2 2018 | $402,525,000 | +168.5% | 3,045,282 | +50.5% | 0.14% | +157.4% |
| Q1 2018 | $149,920,000 | -52.9% | 2,023,489 | -64.6% | 0.05% | -52.2% |
| Q4 2017 | $318,400,000 | +83.2% | 5,722,504 | +49.4% | 0.11% | +66.2% |
| Q3 2017 | $173,753,000 | +56.8% | 3,830,545 | +16.6% | 0.07% | +41.7% |
| Q2 2017 | $110,780,000 | +75.2% | 3,286,251 | +53.9% | 0.05% | +50.0% |
| Q1 2017 | $63,225,000 | -30.7% | 2,135,979 | -35.8% | 0.03% | -31.9% |
| Q4 2016 | $91,231,000 | -63.6% | 3,325,944 | -18.5% | 0.05% | -61.5% |
| Q3 2016 | $250,644,000 | +156.0% | 4,081,486 | -20.5% | 0.12% | +130.2% |
| Q2 2016 | $97,889,000 | +44.7% | 5,133,162 | +48.1% | 0.05% | +47.2% |
| Q1 2016 | $67,652,000 | -43.6% | 3,465,747 | +11.4% | 0.04% | -34.5% |
| Q4 2015 | $120,005,000 | +83.9% | 3,110,566 | +53.0% | 0.06% | +89.7% |
| Q3 2015 | $65,267,000 | +5.8% | 2,032,596 | +0.3% | 0.03% | +11.5% |
| Q2 2015 | $61,684,000 | +217.4% | 2,027,096 | +38.5% | 0.03% | +188.9% |
| Q1 2015 | $19,435,000 | -45.7% | 1,463,549 | -40.9% | 0.01% | -35.7% |
| Q4 2014 | $35,820,000 | -18.1% | 2,475,451 | +19.5% | 0.01% | -12.5% |
| Q3 2014 | $43,725,000 | -10.3% | 2,072,293 | +26.7% | 0.02% | -27.3% |
| Q2 2014 | $48,727,000 | -45.0% | 1,635,702 | -55.7% | 0.02% | -46.3% |
| Q1 2014 | $88,664,000 | +41.8% | 3,689,695 | +20.2% | 0.04% | +41.4% |
| Q4 2013 | $62,542,000 | -58.9% | 3,070,246 | -4.6% | 0.03% | -63.8% |
| Q3 2013 | $152,024,000 | +23.3% | 3,218,800 | -0.6% | 0.08% | +12.7% |
| Q2 2013 | $123,274,000 | – | 3,239,777 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Casdin Capital, LLC | 1,010,330 | $122,472,203 | 13.56% |
| Finepoint Capital LP | 145,357 | $17,620,176 | 8.78% |
| Avoro Capital Advisors LLC | 4,025,000 | $487,910,500 | 7.61% |
| Saturn V Capital Management LP | 118,401 | $14,352,569 | 6.01% |
| Ghost Tree Capital, LLC | 150,000 | $18,183,000 | 5.98% |
| Ikarian Capital, LLC | 3,673 | $44,524,106 | 5.36% |
| ACUTA CAPITAL PARTNERS, LLC | 550 | $7,580,650 | 5.08% |
| Eagle Health Investments LP | 174,212 | $21,117,979 | 4.65% |
| Boxer Capital, LLC | 600,000 | $72,732,000 | 3.87% |
| GREAT POINT PARTNERS LLC | 165,200 | $20,025,544 | 3.65% |